5 results match your criteria: "Institut Gustave Roussy and University of Paris-Sud[Affiliation]"
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Eur J Cancer
March 2021
Medical Oncology Department, Hospital Nuestra Señora de Sonsoles, Ávila, Ávila, Spain. Electronic address:
Article Synopsis
- BRCA1 and BRCA2 gene mutations play a significant role in hereditary breast cancer and are increasingly important for determining eligibility for PARP inhibitor therapies.
- Updated guidelines for BRCA testing are necessary due to the overlap of genetic testing with both preventive measures and treatment strategies for breast cancer patients.
- An expert international group, including various healthcare professionals, developed recommendations to improve genetic counseling, update testing indications for therapy, and streamline the testing process for managing breast cancer effectively.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med
December 2019
From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.).
Background: The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.
Methods: We randomly assigned, in a 1:1 ratio, patients who had previously received docetaxel and an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide) to receive cabazitaxel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targeted inhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily). The primary end point was imaging-based progression-free survival.
Managing Nonmetastatic Castration-resistant Prostate Cancer.
Eur Urol
February 2019
The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. Electronic address:
Context: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a rapidly evolving field that merits detailed investigation.
Objective: To review current nmCRPC management practices and identify opportunities for improving care of nmCRPC patients.
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
Eur Urol
October 2014
Department of Cancer Medicine, Institut Gustave Roussy and University of Paris Sud, Villejuif, France.
Resection margins and prognosis in locally invasive thyroid cancer.
Head Neck
July 2014
Department of Head and Neck Oncology-Head and Neck Surgery, Institut Gustave Roussy and University of Paris-Sud, France.
Background: Invasive thyroid cancer is rare, and the extent of surgery controversial. The purpose of this study was to present and evaluate therapeutic prognostic factors.
Methods: We conducted a retrospective single-center study of differentiated thyroid carcinoma invading the larynx, trachea, and/or esophagus treated surgically with macroscopic complete resection.